ClinicalTrials.gg
RecruitingNCT04974346PAILACCUpdated Jan 25, 2022

Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

A Phase 3 interventional study of Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation and Pelvic definitive concurrent chemoradiation in Cervical Cancer, sponsored by Zhejiang Cancer Hospital. Recruiting at 7 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Zhejiang Cancer Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital — 5 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Zhejiang Cancer Hospital.

Started
2021
the only one that year
Phase 3
Only one
of the 10
Registered
3rd of 10
by date

Among the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, this one is the only one that started in 2021, is the only one in phase 3, and was the 3rd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

5 of the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.

Read the detailed description

This clinical trial enrolled participants with locally advanced cervical cancer with positive pelvic lymph nodes below the common iliac region diagnosed by Positron emission tomography-computed tomography(PET-CT). Participants should be able to receive concurrent cisplatin chemotherapy. No anti-tumor treatment was given before randomization. Participants will be randomly assigned to two groups. The study group will receive radiotherapy of pelvic and para-aorta, concurrent chemotherapy and brachytherapy, and the control group will receive pelvic radiotherapy, concurrent chemotherapy and brachytherapy.

03

Conditions studied

  • Cervical Cancer

Keywords

  • locally advanced cervical cancer
  • para-aortic radiotherapy
  • concurrent radiochemotherapy
  • PET-CT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patients voluntarily participated in the study and signed the
  • 18-75 female
  • Cervical squamous cell carcinoma / adenocarcinoma / adenosquamous cell carcinoma
  • According to International Federation of Gynecology and Obstetrics(FIGO) 2009 stage, stage ⅠB2 - ⅣA with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes diagnosed by PET-CT
  • Cisplatin chemotherapy is acceptable
  • (ECOG) score 0-1
  • The expected survival was more than 6 months
  • Women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate methods during the test
  • According to the judgment of the researcher, those who can comply with the trial protocol

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled severe infection
  • Combined with other malignant tumor patients who need treatment and / or new diagnosis within 5 years
  • The patient has received anti-tumor treatment
  • Liver cirrhosis, decompensated liver disease, chronic renal insufficiency and renal failure
  • History of immunodeficiency, including positive or other acquired congenital immunodeficiency disease
  • Myocardial infarction, severe arrhythmia and grade 2 or more congestive heart failure ( classification)
  • Patients with previous pelvic artery embolization
  • Previous radiotherapy for pelvic malignant tumor
  • There was a history of severe allergic reaction to platinum containing chemotherapy drugs
  • Complications, need to be taken during the treatment of liver and kidney function damage drugs, such as tuberculosis
  • The patients who could not understand the content of the experiment and could not cooperate and refused to sign the
  • Patients with accompanying diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
455 participants (estimated)

Study arms

  • Experimental
    study arm

    External beam radiotherapy: Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy. Concurrent chemotherapy: Weekly cisplatin 40mg/m2 during external beam radiotherapy. Brachytherapy: High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least.

    Radiation: Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation

  • Active comparator
    control arm

    External beam radiotherapy: Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy. Concurrent chemotherapy: Weekly cisplatin 40mg/m2 during external beam radiotherapy. Brachytherapy: HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least.

    Radiation: Pelvic definitive concurrent chemoradiation

Interventions

  • RadiationParaaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation

    The para-aortic area, from left renal vein level to abdominal aorta bifurcation level,will be prophylactic irradiation. The other intervention is the same as control arm.

  • RadiationPelvic definitive concurrent chemoradiation

    Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.

06

What researchers measure

Primary outcomes

  1. Progression-free survival rate

    the percentage of participants in the group whose disease is likely to remain stable

    Time frame: 3-year

Secondary outcomes

  1. Overall survival rate

    the percentage of participants in the group who survives

    Time frame: 3-year

  2. Para-aortic recurrence rate

    the percentage of participants involved by recurrence in the area of para-aortic lymph node

    Time frame: 3-year

  3. Distant recurrence rate

    the percentage of participants involved by recurrence in any organ or tissue except pelvic and para-aortic area

    Time frame: 3-years

  4. Side effects

    side effects associated with treatment

    Time frame: 3-year

  5. Quality of life (QOL) assessed by EORTC QLQ-C30 v3

    an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (assessed by EORTC QLQ-C30 v3 )

    Time frame: 1-month and 6-month

  6. Quality of life (QOL) assessed by EORTC QLQ-CX24

    an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (assessed by EORTC QLQ-CX24)

    Time frame: 1-month and 6-month

07

Study locations

1 of 7 sites recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Xiang Zhang · Contactzhangxiang@zjcc.org.cn · 0086-571-88122048
    • Xiang Zhang · Principal investigator
    • Jianhong Chen · Sub investigator
    • Yeqiang Tu · Sub investigator
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, China
    Active, not recruiting

    Not enrolling at this site.

  • Jinhua Municipal Central Hospital Medical Group
    Jinhua, China
    Active, not recruiting

    Not enrolling at this site.

  • Lishui People's Hospital
    Lishui, China
    Active, not recruiting

    Not enrolling at this site.

  • Ningbo First Hospital
    Ningbo, China
    Active, not recruiting

    Not enrolling at this site.

  • Taizhou Central Hospiatl
    Taizhou, China
    Active, not recruiting

    Not enrolling at this site.

  • Chongqing University Three Gorges Hospital
    Wanzhou, China
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2028, 83 months after the start.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 83 months is close to that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2021
First posted
Jul 23, 2021
StartActual
Aug 2, 2021
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2030
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04974346
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Aug 2, 2021
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Jan 25, 2022

Study contacts

Xiang Zhang
Contact
zhangxiang@zjcc.org.cn
0086-571-88122148

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion